NVAX:NASDAQ
Novavax Inc
၁၂.၆၄ US$
၀.၀၀%
(၀.၀၀) 1D
၁၂.၃၇ US$
arrow_downward
-၂.၁၂% (-၀.၂၇)todayPre-market
Closed: အောက် ၁၄, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Mkt. cap
၂၀၈.၄၉ ဋေ
Avg. vol.
၇.၄၂ သန်း
Volume
၈.၅၇ သောင်း
52-wk high
၁၃.၃၈ US$
52-wk low
၆.၂၀ US$
EPS
-၁.၅၂ US$
Beta
၂.၄၄
Shares outstanding
၁၆.၄၉ ကုဋေ
No. of employees
၇၄၉
Mkt. cap
၂၀၈.၄၉ ဋေ
Avg. vol.
၇.၄၂ သန်း
Volume
၈.၅၇ သောင်း
52-wk high
၁၃.၃၈ US$
52-wk low
၆.၂၀ US$
EPS
-၁.၅၂ US$
Beta
၂.၄၄
Shares outstanding
၁၆.၄၉ ကုဋေ
No. of employees
၇၄၉
News stories
From web sources and news partners
Zacks
·
ပြီးခဲ့သည့် ၁ ရက်
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
News Corp
·
ပြီးခဲ့သည့် ၁ ရက်
Novavax Inc. stock outperforms competitors on strong trading day
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ ရက်
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
24/7 Wall St.
·
ပြီးခဲ့သည့် ၅ ရက်
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees၇၄၉
Founded၁၉၈၇
HeadquartersGaithersburg, မေရီလန်းပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitenovavax.com